158 related articles for article (PubMed ID: 23466230)
1. Design, synthesis and antithrombotic evaluation of novel dabigatran prodrugs containing methyl ferulate.
Yang XZ; Diao XJ; Yang WH; Li F; He GW; Gong GQ; Xu YG
Bioorg Med Chem Lett; 2013 Apr; 23(7):2089-92. PubMed ID: 23466230
[TBL] [Abstract][Full Text] [Related]
2. Synthesis and antithrombotic evaluation of novel dabigatran prodrugs containing a cleavable moiety with anti-platelet activity.
Yang XZ; Yang WH; Xu YG; Diao XJ; He GW; Gong GQ
Eur J Med Chem; 2012 Nov; 57():21-8. PubMed ID: 23043765
[TBL] [Abstract][Full Text] [Related]
3. Dabigatran etexilate, a thrombin inhibitor for the prevention of venous thromboembolism and stroke.
Ieko M
Curr Opin Investig Drugs; 2007 Sep; 8(9):758-68. PubMed ID: 17729188
[TBL] [Abstract][Full Text] [Related]
4. Design, synthesis and antithrombotic evaluation of novel dabigatran etexilate analogs, a new series of non-peptides thrombin inhibitors.
Chen D; Wang S; Diao X; Zhu Q; Shen H; Han X; Wang Y; Gong G; Xu Y
Bioorg Med Chem; 2015 Dec; 23(23):7405-16. PubMed ID: 26537784
[TBL] [Abstract][Full Text] [Related]
5. Antithrombotic activity of HY023016, a novel Dabigatran prodrug evaluated in animal thrombosis models.
Li YZ; Gong GQ; Yang WH; Wang XH; Jiang ML; Zhou Y; Yang XZ; Xu YG; He GW
Thromb Res; 2013 May; 131(5):425-35. PubMed ID: 23535565
[TBL] [Abstract][Full Text] [Related]
6. In-vitro profile and ex-vivo anticoagulant activity of the direct thrombin inhibitor dabigatran and its orally active prodrug, dabigatran etexilate.
Wienen W; Stassen JM; Priepke H; Ries UJ; Hauel N
Thromb Haemost; 2007 Jul; 98(1):155-62. PubMed ID: 17598008
[TBL] [Abstract][Full Text] [Related]
7. A class of novel N-(1-methyl-β-carboline-3-carbonyl)-N'-(aminoacid-acyl)-hydrazines: aromatization leaded design, synthesis, in vitro anti-platelet aggregation/in vivo anti-thrombotic evaluation and 3D QSAR analysis.
Li C; Zhang X; Zhao M; Wang Y; Wu J; Liu J; Zheng M; Peng S
Eur J Med Chem; 2011 Nov; 46(11):5598-608. PubMed ID: 21983333
[TBL] [Abstract][Full Text] [Related]
8. New NO donors with antithrombotic and vasodilating activities, part 25. Hydroxylamine derivatives.
Rehse K; Shahrouri T
Arch Pharm (Weinheim); 1998 Nov; 331(11):365-7. PubMed ID: 9881060
[TBL] [Abstract][Full Text] [Related]
9. Thienopyrimidine-based P2Y12 platelet aggregation inhibitors.
Kortum SW; Lachance RM; Schweitzer BA; Yalamanchili G; Rahman H; Ennis MD; Huff RM; TenBrink RE
Bioorg Med Chem Lett; 2009 Oct; 19(20):5919-23. PubMed ID: 19748783
[TBL] [Abstract][Full Text] [Related]
10. Design, synthesis, and evaluation of 2-substituted ethenesulfonic acid ester derivatives as protein tyrosine phosphatase 1B inhibitors.
Liu J; Jiang F; Jin Y; Zhang Y; Liu J; Liu W; Fu L
Eur J Med Chem; 2012 Nov; 57():10-20. PubMed ID: 23043764
[TBL] [Abstract][Full Text] [Related]
11. New orally active non-peptide fibrinogen receptor (GpIIb-IIIa) antagonists: identification of ethyl 3-[N-[4-[4-[amino[(ethoxycarbonyl) imino]methyl]phenyl]-1,3-thiazol-2-yl]-N-[1-[(ethoxycarbonyl)methyl]pip erid -4-yl]amino]propionate (SR 121787) as a potent and long-acting antithrombotic agent.
Badorc A; Bordes MF; de Cointet P; Savi P; Bernat A; Lalé A; Petitou M; Maffrand JP; Herbert JM
J Med Chem; 1997 Oct; 40(21):3393-401. PubMed ID: 9341914
[TBL] [Abstract][Full Text] [Related]
12. Discovery and synthesis of a novel series of quinoline-based thrombin receptor (PAR-1) antagonists.
Clasby MC; Chackalamannil S; Czarniecki M; Doller D; Eagen K; Greenlee WJ; Lin Y; Tsai H; Xia Y; Ahn HS; Agans-Fantuzzi J; Boykow G; Chintala M; Foster C; Bryant M; Lau J
Bioorg Med Chem Lett; 2006 Mar; 16(6):1544-8. PubMed ID: 16380251
[TBL] [Abstract][Full Text] [Related]
13. Design, synthesis and antithrombotic evaluation of novel non-peptide thrombin inhibitors.
Chen D; Shi J; Liu J; Zhang X; Deng X; Yang Y; Cui S; Zhu Q; Gong G; Xu Y
Bioorg Med Chem; 2017 Jan; 25(2):458-470. PubMed ID: 27884512
[TBL] [Abstract][Full Text] [Related]
14. In-depth study of tripeptide-based alpha-ketoheterocycles as inhibitors of thrombin. Effective utilization of the S1' subsite and its implications to structure-based drug design.
Costanzo MJ; Almond HR; Hecker LR; Schott MR; Yabut SC; Zhang HC; Andrade-Gordon P; Corcoran TW; Giardino EC; Kauffman JA; Lewis JM; de Garavilla L; Haertlein BJ; Maryanoff BE
J Med Chem; 2005 Mar; 48(6):1984-2008. PubMed ID: 15771442
[TBL] [Abstract][Full Text] [Related]
15. [Synthesis and antithrombotic activity of acetylsalicyl ferulic acid-coupling furoxans and nitrates].
Zhou Z; Jiang LY; Zhang YH; Ji H; Sun Y; Peng SX
Yao Xue Xue Bao; 2006 Nov; 41(11):1050-6. PubMed ID: 17262946
[TBL] [Abstract][Full Text] [Related]
16. Guanidine derivatives as combined thromboxane A2 receptor antagonists and synthase inhibitors.
Soyka R; Guth BD; Weisenberger HM; Luger P; Müller TH
J Med Chem; 1999 Apr; 42(7):1235-49. PubMed ID: 10197967
[TBL] [Abstract][Full Text] [Related]
17. [Antithrombotic activity of RU-891 antiaggregant agent].
Spasov AA; Kucheriavenko AF; Tian' M; Anisimova VA
Eksp Klin Farmakol; 2013; 76(6):25-6. PubMed ID: 24003486
[TBL] [Abstract][Full Text] [Related]
18. BIBR-1048 Boehringer Ingelheim.
Mungall D
Curr Opin Investig Drugs; 2002 Jun; 3(6):905-7. PubMed ID: 12137410
[TBL] [Abstract][Full Text] [Related]
19. Design, synthesis and evaluation of nitric oxide releasing derivatives of 3-n-butylphthalide as antiplatelet and antithrombotic agents.
Wang X; Li Y; Zhao Q; Min Z; Zhang C; Lai Y; Ji H; Peng S; Zhang Y
Org Biomol Chem; 2011 Aug; 9(16):5670-81. PubMed ID: 21706121
[TBL] [Abstract][Full Text] [Related]
20. Improving upon the in vitro biological activity of antithrombotic disulfides.
MacDonald JA; Marchand ME; Langler RF
Blood Coagul Fibrinolysis; 2004 Sep; 15(6):447-50. PubMed ID: 15311152
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
